MedTrace Logo

Clinical Study of Pan-cancer DNA Methylation Test in Plasma

NCT05685524 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2023-01-17

No results posted yet for this study

Summary

We intend to establish an efficient method for plasma cfDNA extraction and Bisulfite transformation to facilitate the detection of DNA methylation status using multiplex fluorescence PCR. Meanwhile, we expect to identify several plasma methylation markers that can be highly sensitive for multi-cancer detection. Finally, we will provide a pan-cancer blood test that is easy to operate, low cost, accurate and easy to promote.

Conditions

Interventions

DIAGNOSTIC_TEST

DNA methylation test

Cell-free DNA were extracted from plasma collected from individuals of cancer and non-cancerous disease groups, then the DNA was bisulfite converted and tested by DNA methylation assay based on real-time PCR platform.

Sponsors & Collaborators

  • Wuhan Ammunition Life-tech Co., Ltd

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-08-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05685524 on ClinicalTrials.gov